Peking Union Medical College Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

574

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

34 drugs in development

Approved2

Phase 34

Phase 218

Phase 18

Preclinical8

By Therapeutic Area

top 6

Oncology

1534%

Rare Disease

49%

Cardiovascular

37%

Gastroenterology

25%

Metabolic & Endocrine

25%

Neurology

25%

R&D Momentum

95/100

Pipeline Velocity

71/100

Trial Completion Rate

91/100

Pipeline Concentration

24/100

Pipeline Freshness

49/100

Strategic Signals

↗Active in Gastroenterology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 17, 2026

Completed

Gut Microbiota and Pulmonary Complications After Non Cardiac Elective Surgery in Elderly Patients

Sep 17, 2026

Completed

Comparison Study of Conventional Peroral Endoscopic Myotomy (POEM) and Different Modified Procedures of POEM for Achalasia

Sep 17, 2026

Completed

Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding

Sep 17, 2026

Enrolling by invitation

Exploratory Study of a Novel Dual Target Molecular Probe NI-FAPI-04 for Intra Irradiation Therapy of Hypoxic and Fibroblast Activation Protein Related Tumors

Sep 10, 2026

Recruiting

[68Ga]Ga-HBED-CC-PEG6-Exendin-4 PET/CT Imaging in the Diagnosis of Insulinoma

Earlier

Sep 5, 2026TrialPost-Market Application Study and Efficacy/Safety Evaluation of a Vascular Interventional Robotic System for Cerebral Angiography: A Multicenter Randomized Controlled Trial

Sep 5, 2026TrialA Prospective, Phase II Clinical Trial Using the Combination of Zanubrutinib, Rituximab and High-dose Intravenous Methotrexate With Intravitreal Methotrexate Injection Therapy for the Treatment of Primary Intraocular Lymphoma

Sep 5, 2026TrialLongitudinal Wastewater Monitoring of Antimicrobial Resistance Genes Across Functional Hospital Areas and Its Association With Clinical Carbapenem-Resistant Organism Infections: A Prospective Observational Cohort Study

3 more events

Sep 3, 2026TrialDZD9008 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutations: Cohort Study

Sep 3, 2026TrialA Randomized Controlled Clinical Study on the Precise Positioning of Double-lumen Bronchial Intubation Guided by Medical Imaging-based Airway Three-dimensional Reconstruction Technology

Sep 2, 2026TrialWearable Device-Based Screening for Anemia Risk

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

QbrexzaOct 17, 2028 QbrexzaDec 10, 2029 QbrexzaJul 18, 2030 Qbrexza5 patentsFeb 28, 2033

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(3 drugs)

—

Cardiovascular(3 drugs)

Gastroenterology(2 drugs)

—

Gastroenterology(2 drugs)

Hematology(1 drug)

—

Hematology(1 drug)

Metabolic & Endocrine(2 drugs)

—

Metabolic & Endocrine(2 drugs)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(15 drugs)

—

Oncology(15 drugs)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Rare Disease(4 drugs)

—

Rare Disease(4 drugs)

Unknown / Other(14 drugs)

—

Unknown / Other(14 drugs)

Regulatory

Regulatory Timeline

20182 events

FDAJun 28

Qbrexza — QBREXZA

Application NDA210361 (NDA)

FDAJun 28

Qbrexza — QBREXZA

Application NDA210361 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)